Artivion, Inc. (NYSE:AORT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $44.1667.

A number of analysts have commented on the company. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Canaccord Genuity Group restated a “buy” rating and set a $36.00 price objective on shares of Artivion in a research report on Tuesday, June 16th. Needham & Company LLC reduced their target price on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a research note on Friday, April 10th. Finally, Weiss Ratings downgraded shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th.

Artivion Stock Down 0.3%

NYSE AORT opened at $23.91 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The firm has a 50-day simple moving average of $24.60 and a 200 day simple moving average of $34.52. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The stock has a market cap of $1.16 billion, a PE ratio of 99.63 and a beta of 1.26.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion in the 3rd quarter worth approximately $27,000. Rockefeller Capital Management L.P. boosted its stake in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares in the last quarter. Larson Financial Group LLC grew its position in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the period. USA Financial Formulas grew its position in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the period. Finally, KBC Group NV acquired a new position in Artivion during the fourth quarter worth $65,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.